Radiation therapy can be effectively delivered in more focused, intensive, and shorter-course treatment regimens that offer patients at least equivalent—and in some cases superior—outcomes in several tumor types, thus helping to mitigate challenging adverse effects of standard approaches.
Puneeth Iyengar, MD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the rationale behind the use of hypofractionated radiation as a treatment for patients with non–small cell lung cancer.
In a propensity-matched analysis of a national cancer registry, patients who underwent radical cystectomy or concurrent chemoradiation to treat urothelial cancer demonstrated statistically similar median overall survival rates. Further analysis suggests that the hazard ratios between the two treatments change over time and is hypothesis generating.
For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields and employing a personalized transducer array, delivered electric field intensities that exceeded therapeutic intensities in 3 different tumor locations. The findings may aid treatment planning when using the NovoTAL System, which optimizes therapeutic delivery in 2 orthogonal directions to the gross tumor volume and proximal peri-tumoral brain zone.
Men with intermediate prostate cancer who received extreme hypofractionated radiotherapy reported a low incidence of side effects, with no significant differences compared with a similar cohort of men who received conventional fractionation after 2 years of treatment.
A strategy to stimulate an immune response in radiation-damaged tumor cells resulted in preliminary evidence of activity—including longer survival—in a small clinical trial of patients with metastatic breast cancer.
Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.
Patients with head and neck cancer whose disease is associated with KRAS variant had significantly better progression-free survival and overall survival when treated with the monoclonal antibody cetuximab, according to findings of a retrospective analysis of a randomized trial.
Patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity when treated with pelvic intensity-modulated radiation therapy as opposed to standard pelvic radiation therapy.
David T. Marshall, MD, MS, professor, director, Medical Residency Program, Department of Radiation Oncology, Medical University of South Carolina, discusses the ASCENDE-RT trial, which compared dose-escalated external beam radiation therapy versus low-dose-rate brachytherapy for men with unfavorable-risk localized prostate cancer.